Heirloom Wealth Management Buys 1,416 Shares of Novo Nordisk A/S (NYSE:NVO)

Heirloom Wealth Management grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,950 shares of the company’s stock after buying an additional 1,416 shares during the period. Novo Nordisk A/S accounts for about 3.0% of Heirloom Wealth Management’s investment portfolio, making the stock its 11th largest position. Heirloom Wealth Management’s holdings in Novo Nordisk A/S were worth $7,857,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Westside Investment Management Inc. grew its holdings in shares of Novo Nordisk A/S by 83.3% in the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after purchasing an additional 649 shares in the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD purchased a new position in Novo Nordisk A/S during the third quarter worth $2,408,000. Lazard Asset Management LLC boosted its stake in Novo Nordisk A/S by 182.2% during the third quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock worth $135,883,000 after buying an additional 964,640 shares during the period. Benedict Financial Advisors Inc. boosted its stake in Novo Nordisk A/S by 94.0% during the third quarter. Benedict Financial Advisors Inc. now owns 44,292 shares of the company’s stock worth $4,028,000 after buying an additional 21,457 shares during the period. Finally, CENTRAL TRUST Co boosted its stake in Novo Nordisk A/S by 111.6% during the third quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock worth $546,000 after buying an additional 3,166 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.0 %

Novo Nordisk A/S stock traded down $0.05 during trading hours on Friday, reaching $122.70. The stock had a trading volume of 5,181,119 shares, compared to its average volume of 4,882,816. The company has a market cap of $550.62 billion, a price-to-earnings ratio of 45.36, a PEG ratio of 2.08 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The business’s 50 day moving average price is $126.39 and its 200-day moving average price is $110.72. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were issued a dividend of $0.664 per share. The ex-dividend date of this dividend was Friday, March 22nd. This represents a dividend yield of 0.9%. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio is 49.17%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on NVO shares. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. Finally, UBS Group began coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.